Table 4.
Prognostic factors analysis in HR + /HER2- breast cancer
| Factors | N | Events (%) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| X2 | P-value | HR (95% CI) | P-value | |||
| All patients | 418 | 21(5.0) | ||||
| Age | 0.339 | 0.56 | ||||
| < 50 | 213 | 12(5.6) | ||||
| ≥ 50 | 205 | 9(4.4) | ||||
| Menstrual status | 0.927 | 0.336 | ||||
| Premenopausal | 216 | 13(6.0) | ||||
| Postmenopausal | 202 | 8(4.0) | ||||
| T stage | 4.497 | 0.034 | ||||
| T1, T2 | 319 | 12(3.8) | ref | |||
| T3, T4 | 99 | 9(9.1) | 2.165(0.843–4.476) | 0.077 | ||
| N stage | 5.902 | 0.015 | ||||
| N0 | 187 | 4(2.1) | ref | |||
| N + | 231 | 17(7.4) | 3.139(1.425–7.034) | 0.024 | ||
| Histological type | 0.084 | 0.772 | ||||
| IDC | 370 | 19(5.1) | ||||
| Others | 48 | 2(4.2) | ||||
| Histological grade | 5.564 | 0.018 | ||||
| I、II | 224 | 6(2.7) | ref | |||
| III | 194 | 15(7.7) | 1.907(0.662–3.419) | 0.062 | ||
| ki67 index | 0.066 | 0.797 | ||||
| < 14% | 47 | 2(4.3) | ||||
| ≥ 14% | 371 | 19(5.1) | ||||
| P53 status | 5.134 | 0.023 | ||||
| Negative | 239 | 7(2.9) | ref | |||
| Positive | 179 | 14(7.8) | 2.675(1.037–5.983) | 0.038 | ||
| HER2 status | 0.218 | 0.641 | ||||
| 0 expression | 159 | 9(5.7) | ||||
| Low expression | 259 | 12(4.6) | ||||
| AR status | 6.529 | 0.011 | ||||
| Negative | 73 | 8(11.0) | ref | |||
| Positive | 345 | 13(3.8) | 0.653(0.237–0.986) | 0.033 | ||
| EGFR status | 1.426 | 0.232 | ||||
| Negative | 288 | 12(4.2) | ||||
| Positive | 130 | 9(6.9) | ||||
| CK5/6 status | 1.943 | 0.163 | ||||
| Negative | 361 | 16(4.4) | ||||
| Positive | 57 | 5(8.8) | ||||
| Surgery | 0.005 | 0.943 | ||||
| Conservative | 82 | 4(4.9) | ||||
| Mastectomy | 336 | 17(5.1) | ||||
| Radiotherapy | 0.791 | 0.374 | ||||
| Yes | 348 | 16(4.6) | ||||
| No | 70 | 5(7.1) | ||||
| NAC effect | 0.194 | 0.659 | ||||
| pCR | 30 | 1(3.3) | ||||
| non-pCR | 388 | 20(5.2) | ||||
IDC invasive ductal carcinoma, NAC neoadjuvant chemotherapy